The biopharmaceutical unit of Korea’s Samsung group deliberately kept quiet on the option that US biotech Biogen (Nasdaq: BIIB) had to increase its share in their joint venture focused on biosimilars.
That is the ruling of the Financial Services Commission, the South Korean financial regulator, which had been investigating the conduct of Samsung BioLogics and its auditor in the case.
The company was found guilty of violating accounting standards by intentionally omitting information regarding the agreement with Biogen in its public disclosure on their joint venture, which goes by the name Samsung Bioepis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze